{
    "root": "a5511d66-5602-4b66-88ad-66b4532fdfe1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Risperidone",
    "value": "20230915",
    "ingredients": [
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "Risperidone",
            "code": "L6UH7ZF8HC"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "CALCIUM CARBONATE",
            "code": "H0G9379FGK"
        },
        {
            "name": "CALCIUM SULFATE, UNSPECIFIED FORM",
            "code": "WAT0DDB505"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        }
    ],
    "indications": "Risperidone is an atypical antipsychotic indicated for: • Treatment of schizophrenia ( 1.1 ) • As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) • Treatment of irritability associated with autistic disorder ( 1.3 )",
    "contraindications": "Table 1. Recommended Daily Dosage by Indication\n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              Initial Dose\n                           \n                           \n                              Titration\n                              \n                              (Increments)\n                           \n                           \n                              Target Dose\n                           \n                           \n                              Effective Dose Range\n                           \n                        \n                     \n                     \n                        \n                           \n                              \n                                 Schizophrenia: adults (2.1)\n                                 \n                              \n                           \n                           \n                              2 mg\n                           \n                           \n                              1 to 2 mg\n                           \n                           \n                              4 to 8 mg\n                           \n                           \n                              4 to 16 mg\n                           \n                        \n                        \n                           \n                              \n                                 Schizophrenia: adolescents (2.2)\n                                 \n                              \n                           \n                           \n                              0.5 mg\n                           \n                           \n                              0.5 to 1 mg\n                           \n                           \n                              3 mg\n                           \n                           \n                              1 to 6 mg\n                           \n                        \n                        \n                           \n                              \n                                 Bipolar mania: adults (2.2)\n                                 \n                              \n                           \n                           \n                              2 to 3 mg\n                           \n                           \n                              1 mg\n                           \n                           \n                              1 to 6 mg\n                           \n                           \n                              1 to 6 mg\n                           \n                        \n                        \n                           \n                              \n                                 Bipolar mania: children and\n                                 \n                                 adolescents (2.2)\n                                 \n                              \n                           \n                           \n                              0.5 mg\n                           \n                           \n                              0.5 to 1 mg\n                           \n                           \n                              1 to 2.5 mg\n                           \n                           \n                              1 to 6 mg\n                           \n                        \n                        \n                           \n                              \n                                 Irritability in autistic disorder (2.3)\n                                 \n                              \n                           \n                           \n                              0.25 mgCan increase to0.5 mg by Day 4:(body weight less than 20 kg)\n                                 0.5 mgCan increase to1 mg by Day 4:(body weight greater than or equal to 20 kg)\n                           \n                           \n                              After Day 4, at intervals of > 2 weeks:0.25 mg(body weight less than 20 kg)\n                                 0.5 mg(body weight greater than or equal to 20 kg)\n                           \n                           \n                              0.5 mg:(body weight less than 20 kg)\n                                 1 mg:(body weight greater than or equal to 20 kg)\n                           \n                           \n                              0.5 to 3 mg\n                           \n                        \n                     \n                  \n                  Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily. May increase to dosages above 1.5 mg twice daily at intervals of one week or longer.",
    "warningsAndPrecautions": null,
    "adverseReactions": "Risperidone is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the risperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone."
}